Molecular Formula | C20H30BrNO3· H2O |
Molar Mass | 430.38 |
Melting Point | 230-232°C |
Water Solubility | Freely soluble |
Solubility | H2O: soluble10mg/mL |
Appearance | Shape powder, color white |
Storage Condition | Inert atmosphere,Room Temperature |
Stability | Stable. Incompatible with strong oxidizing agents. |
MDL | MFCD00792907 |
Physical and Chemical Properties | Bioactive Ipratropium bromide are muscarinic antagonists, bronchodilators, and are AtropineN isopropyl salts. |
Hazard Symbols | Xn - Harmful![]() |
Risk Codes | R20/22 - Harmful by inhalation and if swallowed. R36 - Irritating to the eyes |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
RTECS | YM3700000 |
Toxicity | LD50 in male, female mice (mg/kg): 1001, 1083 orally; 12.29, 14.97 i.v.; 300, 340 s.c.; LD50 in male, female rats (mg/kg): 1663, 1779 orally; 15.89, 15.70 i.v. (Sarafana) |
Raw Materials | Methyl bromide endo-(±)-8-aza-8-isopropylbicyclo[3.2.1]oct-3-yl (hydroxymethyl)phenylacetate |
Solubility | H2O: 10 mg/mL |
pharmacology toxicology
Ipratropium bromide is also known as Haizhu Asperidine, Isopropatropine, Isopropyl Scopolamine, Isopropyl Atropine, Isopropyl Atropine Bromide, Isopropyl Atropine Bromide, Isopropyl Bromide, Isopropyl Bromide, Isopropyl Bromide, It is a white crystalline powder with bitter taste. Melting point 232 ℃-233 ℃. Soluble in water, slightly soluble in ethanol, insoluble in other organic solvents. Chemical name: Brominated α-(hydroxymethyl)-phenylacetic acid -8-methyl -8-isopropyl-azacyclic [3,2,1]-3-octyl ester. It is an anticholinergic drug, which has a strong relaxation effect on bronchial smooth muscle, and has an antiasthmatic effect on chronic obstructive pulmonary disease. Its effect is more obvious, the effect is fast, and the duration is longer. Ipratropium bromide also has the effect of controlling the secretion of mucus glands and improving cilia movement, thereby reducing sputum obstruction to improve ventilation, and the reduction of sputum also reduces bronchospasm caused by bronchial stimulation. It is used to prevent and treat bronchial asthma and asthma-type chronic bronchitis, especially for patients who cannot tolerate such drugs due to muscle tremor and tachycardia caused by β-receptor agonists. This product can be combined with β-receptor agonists to enhance the curative effect. For example, it can be combined with fenoterol to make aerosol (BERODU-AL) for asthma, chronic bronchitis and emphysema. Compared with β-adrenergic receptor stimulants (such as isoproterenol), this product has less cardiovascular side effects. Compared with β2-receptor stimulants (such as salbutamol), this product has a strong effect on sputum volume regulation.
Indications
It is used to prevent and treat bronchial asthma and asthmatic chronic bronchitis, especially for patients who cannot tolerate such drugs due to muscle tremor and tachycardia caused by β-receptor agonists. This product can be combined with β-receptor agonists to enhance the curative effect. For example, it can be combined with fenoterol to make aerosol (BERODU-AL) for asthma, chronic bronchitis and emphysema.
usage and dosage
Spray inhalation. 40~80 μg once, 2~4 times a day. When using, first remove the cover cap, put the cover cross eye on the nozzle, put the bottle upside down, the cover is contained in the mouth, aim at the throat, press the nozzle on the valve while inhaling, inhale the sprayed liquid medicine, hold your breath for a moment. If necessary, press the suction again as above. Aerosol: 0.025% solution. Tablets: 10mg/tablet.
Overdose
Severe anti-cholinergic drug poisoning can be treated with cholinesterase inhibitors.
adverse reactions
the adverse reactions of ipratropium bromide are similar to atropine, which can cause palpitations, headache, dizziness, nervousness, nausea, vomiting, gastrointestinal pain, tremor, blurred vision, dry mouth, cough, dysuria, respiratory symptoms and rash.
in vitro studies
The combination of Ipratropium bromide and Formoterol partially protects the lung from chronic inflammation and enlarges the lung, reducing neutrophils by inhibiting the activity of MMP-9. Ipratropium bromide(1 nM) significantly increased calcium ions, decreased forward scattering and increased Annexin-V binding. After Ipratropium bromide treatment, hemolysis increased slightly but significantly. Ipratropium bromide cause suicide red blood cell death or eryptosis, mainly due to calcium stimulation.
In vivo studies
In resting horses, Ipratropium dry powder inhalation (DPI) at a dose of 2400 mg/horse is an effective bronchodilator, and has little effect on the upper airway caliber during recovery. In cadmium-treated rats, Ipratropium significantly attenuated parenchymal inflammatory cell influx and observed crowded related lung lesions. Ipratropium partially protects the lung from inflammation by reducing neutrophil infiltration. In guinea pig tracheal smooth muscle, Ipratropium is an antagonist that inhibits the anterior binding muscarinic inhibitory receptor of the pulmonary parasympathetic nerve. Ipratropium also proved to be a powerful antagonist of muscarinic inhibitory receptors. In the horse's tidal respiration (incremental Pplmax) and pulmonary resistance (RL), the Ipratropium reduces the maximum change in thoracic pressure and increases dynamic compliance (Cdyn).